Messenger RNA vaccines against Covid-19 do not increase the risk of serious cardiovascular problems (heart attack, stroke or pulmonary embolism) in people under 75, underlines Tuesday a study published by the Medicines Agency.
Read alsoFirst “promising” results for a messenger RNA vaccine against AIDS
As part of the enhanced vaccine monitoring system, Epi-Phare, a structure associating Health Insurance (Cnam) and the Medicines Agency (ANSM), conducted a study on the risk of serious cardiovascular event (excluding myocarditis and pericarditis) within three weeks of injection of an mRNA or adenovirus vaccine.
“Safety of mRNA vaccines” confirmed
This study focused on all adults aged 18 to 74, vaccinated or not, admitted to hospital in France between December 27, 2020 and July 20, 2021 for acute myocardial infarction, ischemic stroke or haemorrhagic, or pulmonary embolism. Its results confirm the "
safety of mRNA vaccines
" (those from Pfizer and Moderna) "
with respect to the risk of a serious cardiovascular event in adults
" which could have occurred during the three weeks following the first or second doses of vaccines.
On the other hand, adenovirus vaccines (those from AstraZeneca and Janssen) appear “
associated with a slight increase in the risk of myocardial infarction and pulmonary embolism in adults, within two weeks of injection
”. These adenovirus vaccines are little used in France, recalls the ANSM. “
For us, this is a major result which confirms the safety of messenger RNA vaccines in people under 75.
“, commented to AFP Rosemary Dray-Spira, epidemiologist and deputy director of the structure of Epi-Phare.
The results of this survey corroborate those of other international studies.
A previous study, which focused on people aged 75 or over, had not shown an increase in cardiovascular risk after each of the two doses of the Pfizer vaccine.
Read alsoThe boss of Pfizer at
We will soon resume normal life
Another Epi-Phare study on people aged 12 to 50 had shown that Pfizer and especially Moderna vaccines increased the risk of myocarditis or pericarditis occurring within 7 days of vaccination, and more often. in men under the age of 30.
Covid-19 disease is itself strongly associated with a risk of cardiovascular complications, also wishes to recall the ANSM.